Disease · MONDO_0013792
intracerebral hemorrhage
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. intracerebral hemorrhage. Diseases, record MONDO_0013792. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013792
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs65
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EPTACOG ALFA (ACTIVATED) | CHEMBL2108334 | Protein | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| TRANEXAMIC ACID | CHEMBL877 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| MINOCYCLINE | CHEMBL1434 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TENECTEPLASE | CHEMBL2108791 | Enzyme | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DEFEROXAMINE MESYLATE | CHEMBL1234 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CLEVIDIPINE | CHEMBL1237132 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| COLCHICINE | CHEMBL107 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOXETINE | CHEMBL41 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NICARDIPINE HYDROCHLORIDE | CHEMBL1200326 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEFEROXAMINE | CHEMBL556 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 65
See all 65 drugsTargets66
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CACNA1C | Voltage-gated L-type calcium channel | 4 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 4 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 4 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 4 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/779 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 4 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 3 | Adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 3 | Adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| F10 | Coagulation factor X | 3 | Coagulation factor X inhibitor | Unknown | https://conductscience.org/library/genes/2159 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| PLAT | Tissue-type plasminogen activator | 3 | Tissue-type plasminogen activator exogenous protein; Tissue-type plasminogen activator inhibitor | Phase 3 | https://conductscience.org/library/genes/5327 | Drugs and targets |
1 to 10 of 66
See all 66 targetsTrials76
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01176565 | Antihypertensive Treatment of Acute Cerebral Hemorrhage-II | Phase 3 | 1,000 | 2017-04-25 | Intracerebral Hemorrhage | NICARDIPINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02175225 | Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial | Phase 2 | 294 | 2019-05-30 | Intracerebral Hemorrhage | DEFEROXAMINE MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00224770 | Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation | Phase 2 | 141 | 2015-06-18 | Intracerebral Hemorrhage | ALTEPLASE | Its record names the disease | ClinicalTrials.gov |
| NCT00810888 | The Spot Sign for Predicting and Treating ICH Growth Study | Phase 2 | 92 | 2018-01-08 | Intracerebral Hemorrhage | EPTACOG ALFA (ACTIVATED) | Its record names the disease | ClinicalTrials.gov |
| NCT00415610 | Antihypertensive Treatment in Acute Cerebral Hemorrhage | Phase 1 | 60 | 2015-09-07 | Intracerebral Hemorrhage, Hypertension, Stroke | NICARDIPINE | Its record names the disease | ClinicalTrials.gov |
| NCT03496545 | Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury | Phase 1/2 | 47 | 2021-06-24 | Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage | BROMOCRIPTINE | Its record names the disease | ClinicalTrials.gov |
| NCT01662895 | High-Dose Deferoxamine in Intracerebral Hemorrhage | Phase 2 | 42 | 2019-05-30 | Intracerebral Hemorrhage | DEFEROXAMINE, DEFEROXAMINE MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00666328 | Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE) | Phase 3 | 37 | 2013-04-08 | Hypertension, Hemorrhage | CLEVIDIPINE | Its record names the disease | ClinicalTrials.gov |
| NCT03338998 | Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). | Phase 2 | 32 | 2021-06-07 | Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH) | SIPONIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT04088630 | Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage | Early phase 1 | 28 | 2025-01-14 | Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal | FINGOLIMOD | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 76
See all 76 trialsComparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Any Serious Adverse Event Within the 90-day Study Period | 100 of 500 | 128 of 500 | 1,000 | NCT01176565 | Trial comparisons |
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Hypotension Within 72 Hours | 3 of 500 | 6 of 500 | 1,000 | NCT01176565 | Trial comparisons |
Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Neurological Deterioration Within 24 Hours, Defined by a Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score From Baseline, Not Related to Sedation or Hypnotic-agent Use and Sustained for at Least 8 Hours. | 40 of 500 | 55 of 500 | 1,000 | NCT01176565 | Trial comparisons |
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Treatment-related Serious Adverse Event Within 72 Hours of Randomization | 6 of 500 | 8 of 500 | 1,000 | NCT01176565 | Trial comparisons |
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: serious adverse events | 100 of 500 | 128 of 500 | 1,000 | NCT01176565 | Trial comparisons |
Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.) | 104 of 426 | 85 of 450 | 876 | NCT01176565 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Number of Subjects With Serious Adverse Events Within 7 Days | 24 of 144 | 26 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Number of Patients With Symptomatic Cerebral Edema | 9 of 144 | 5 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Number of Subjects Experiencing Serious Adverse Events | 39 of 144 | 49 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Adverse Event of Special Interest: Number of Patients With New Visual or Auditory Changes | 3 of 144 | 4 of 147 | 291 | NCT02175225 | Trial comparisons |
1 to 10 of 33
See all 33 comparisons in its trialsPapers from its trials166
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013792
GET https://conductscience.org/api/diseases/v1/MONDO_0013792/drugs?page=2